Amylyx Pharmaceuticals Inc (AMLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 0 | 0 | 0 | -665 | 416 |
| Cost of Goods | N/A | N/A | N/A | 0 | 809 |
| Gross Profit | N/A | N/A | N/A | -665 | -393 |
| Operating Expenses | 36,027 | 42,857 | 37,803 | 39,989 | 76,077 |
| Operating Income | -36,027 | -42,857 | -37,803 | -40,654 | -75,661 |
| Other Income | 1,641 | 1,414 | 1,896 | 2,473 | 2,957 |
| Pre-tax Income | -34,386 | -41,443 | -35,907 | -38,181 | -72,704 |
| Income Tax | N/A | N/A | N/A | -635 | N/A |
| Net Income Continuous | -34,386 | -41,443 | -35,907 | -37,546 | -72,704 |
| Net Income | $-34,386 | $-41,443 | $-35,907 | $-37,546 | $-72,704 |
| EPS Basic Total Ops | -0.37 | -0.46 | -0.42 | -0.54 | -1.07 |
| EPS Basic Continuous Ops | -0.37 | -0.46 | -0.42 | -0.54 | -1.07 |
| EPS Diluted Total Ops | -0.37 | -0.46 | -0.42 | -0.54 | -1.07 |
| EPS Diluted Continuous Ops | -0.37 | -0.46 | -0.42 | -0.54 | -1.07 |
| EPS Diluted Before Non-Recurring Items | -0.37 | -0.46 | -0.42 | -0.55 | -0.53 |
| EBITDA(a) | $-37,150 | $-44,239 | $-39,350 | $-42,285 | $-77,745 |